NASDAQ:ARDM Aradigm (ARDM) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free ARDM Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.15▼$0.3852-Week Range N/AVolumeN/AAverage Volume97,091 shsMarket Capitalization$761,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Aradigm alerts: Email Address Ad Behind the MarketsWill this $2 AI stock double overnight?It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!Click here to learn more >>> About Aradigm Stock (NASDAQ:ARDM)Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. Its lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin, including Linhaliq and Lipoquin that are delivered by inhalation for the management of infections associated with severe respiratory diseases, including non-cystic fibrosis bronchiectasis, cystic fibrosis, and non-tuberculosis mycobacterium. The company is also developing inhaled ciprofloxacin formulations for treatment of patients with cystic fibrosis, and has tested for the prevention and treatment of inhaled bioterrorism infections, such as Coxiella burnetii or Q fever, inhalation anthrax, tularemia, melioidosis and pneumonic plague. Aradigm Corporation has collaboration agreements with Grifols, S.A. The company was founded in 1991 and is headquartered in Hayward, California.Read More Ad Behind the MarketsWill this $2 AI stock double overnight?It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!Click here to learn more >>> ARDM Stock News HeadlinesNovember 21, 2023 | investing.comFirst International Bank of Israel Ltd (FIBI)November 10, 2023 | investing.comAltshuler Shaham Financial LTD (ALTF)April 25, 2024 | Behind the Markets (Ad)Will this $2 AI stock double overnight?It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!May 1, 2023 | marketwatch.comNon-Cystic Fibrosis Bronchiectasis Market Forecast to 2030April 22, 2023 | investing.comAerodrome Group Ltd (ARDM)March 17, 2023 | finance.yahoo.comAerodrome Group Ltd (ARDM.TA)December 28, 2022 | investopedia.comHow and Why Google Glass FailedSee More Headlines Receive ARDM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aradigm and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2018Today4/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical Equipment Sub-IndustryN/A Current SymbolNASDAQ:ARDM CUSIPN/A CIK1013238 Webwww.aradigm.com Phone510-265-9000FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,700,000.00 Net Margins-374.80% Pretax MarginN/A Return on EquityN/A Return on Assets-374.15% Debt Debt-to-Equity RatioN/A Current Ratio1.23 Quick Ratio1.23 Sales & Book Value Annual Sales$14.47 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.83) per share Price / BookN/AMiscellaneous Outstanding Shares15,220,000Free FloatN/AMarket Cap$761,000.00 OptionableOptionable Beta1.57 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. John M. Siebert (Age 79)Exec. Chairman, Interim Principal Exec. Officer & Acting Principal Financial Officer Dr. Juergen Froehlich M.D. (Age 62)MBA, FCPh, Chief Medical Officer Dr. Igor Gonda (Age 71)Consultant Ms. Nancy E. Pecota (Age 59)Consultant Lisa ThomasCorp. ControllerKey CompetitorsTivic Health SystemsNASDAQ:TIVCNuwellisNASDAQ:NUWEENDRA Life SciencesNASDAQ:NDRASientraNASDAQ:SIENQBellerophon TherapeuticsNASDAQ:BLPHView All Competitors ARDM Stock Analysis - Frequently Asked Questions How were Aradigm's earnings last quarter? Aradigm Co. (NASDAQ:ARDM) released its quarterly earnings results on Thursday, November, 15th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.21) by $0.03. The company earned $0.28 million during the quarter. What other stocks do shareholders of Aradigm own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aradigm investors own include Amarin (AMRN), CRISPR Therapeutics (CRSP), Vaxart (VXRT), Nabriva Therapeutics (NBRV), Novavax (NVAX), VBI Vaccines (VBIV), Aduro Biotech (ADRO), Anavex Life Sciences (AVXL), OpGen (OPGN) and This page (NASDAQ:ARDM) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American Alternative1970’s computer coder issues shocking A.I. warningTradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aradigm Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
